Slide background

A new approach to addressing difficult-to-treat depression

Slide background

Naurex's clinical trials

About Naurex

Naurex is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat depression as well as orphan and other challenging diseases of the central nervous system (CNS) treated in specialty settings. All of our programs, including two rapid-acting antidepressants currently in clinical development, stem from our proprietary platform for discovering novel compounds that act at the NMDA receptor (NMDAR) through a new mechanism of action to modulate neuronal plasticity.

Learn more about Naurex »

Our Programs

Naurex has two therapies for depression currently in clinical development. Our lead compound, GLYX-13, has shown rapid-acting antidepressant activity with excellent safety in a Phase 2a clinical trial in subjects who had failed treatment with existing agents. GLYX-13 is currently in a Phase 2b study as adjunctive therapy for major depressive disorder. Naurex’s 2nd-generation antidepressant, NRX-1074, is currently in Phase 1 clinical studies. Naurex is also advancing additional molecules from its NMDAR modulation platform into clinical development for the treatment of other challenging CNS diseases.

Learn more about our programs »